Quiver Bioscience
Quiver Bioscience develops therapeutics that translate human neuronal biology into new treatments for brain disorders. The company combines patient-derived stem-cell disease models, advanced single-cell imaging, multi-omics, and a proprietary “Genomic Positioning System” with AI/ML to identify targets and nominate candidate molecules. Its platform supports modalities including antisense oligonucleotides (ASO) and optogenetics and advances programs from target discovery through preclinical and clinical development. Quiver operates as a technology-driven B2B therapeutics developer that partners with pharmaceutical companies and researchers to de-risk neuroscience programs. Active pipelines include programs for chronic pain (Nav1.7, Nav1.8) and several seizure and neurodevelopmental disorders.
Quiver Bioscience
Quiver Bioscience develops therapeutics that translate human neuronal biology into new treatments for brain disorders. The company combines patient-derived stem-cell disease models, advanced single-cell imaging, multi-omics, and a proprietary “Genomic Positioning System” with AI/ML to identify targets and nominate candidate molecules. Its platform supports modalities including antisense oligonucleotides (ASO) and optogenetics and advances programs from target discovery through preclinical and clinical development. Quiver operates as a technology-driven B2B therapeutics developer that partners with pharmaceutical companies and researchers to de-risk neuroscience programs. Active pipelines include programs for chronic pain (Nav1.7, Nav1.8) and several seizure and neurodevelopmental disorders.
TL;DR
Founded: 2013
Headquarters: Cambridge, Massachusetts, USA
Stage / Funding: Grant-funded; recent Phase II SBIR from NINDS ($2.15M)
Focus: AI-driven discovery for CNS disorders and chronic pain using human neuronal models and optogenetic high-throughput assays
Platform highlights: Genomic Positioning System (GPS) + Swarm optogenetic all-optical electrophysiology
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Central nervous system disorders and chronic pain; discovery and preclinical development of therapeutics.
Founded
2013
Industry
Biotechnology
Tech Stack
Funding Track Record
2150000
Three-year Phase II SBIR to advance platform capabilities and an in vitro/in silico predictor of CNS drug safety
Investor Signal
“Receives non-dilutive grant funding from U.S. federal institutes (notably NINDS)”